Outcomes of CDK4/6 Inhibitors vs Weekly Paclitaxel in the Treatment of Patients With ER+/HER2− Advanced Breast Cancer With Impending or Established Visceral Crisis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
Breast Cancer Res Treat 2023 Aug 16;[EPub Ahead of Print], R Behrouzi, AC Armstrong, SJ HowellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.